Renji Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, was built in 1844. It is a Class A tertiary hospital integrating medical service, education and scientific research. The Shanghai Human Sperm Bank was established in 1992 at Renji Hospital, and the Center for Reproductive Medicine was founded in 2001. Currently, the center offers a wide range of medical services including diagnostic and therapeutic technology projects for infertility, eugenics and fertility preservation and reconstruction. The reproductive medicine team of Renji Hospital is highly competent. The chief expert, Academician Chen Zijiang, an academician of Chinese Academy of Sciences and the World Academy of Sciences for the advancement of science in developing countries (TWAS), directs the Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics (located in Renji Hospital). The director of the department, Professor Sun Yun, is recognized as a leading talent in Shanghai and holds the title of Shanghai Craftsman. She also serves as Director of the Reproductive Medicine Branch of the Shanghai Medical Association and Director of the Shanghai Quality Control Center for Assisted Reproductive Technology (based at Renji Hospital). There are currently 79 clinical medical staffs, 7 full-time Principal Investigators (PIs) in key laboratory, 25 persons with senior professional titles, 5 doctoral supervisors, and 3 master supervisors.

The Reproductive Medicine Department of Renji Hospital provides a complete range of subspecialties, including reproductive gynecology, reproductive andrology, reproductive genetics, reproductive endoscopic surgery, and traditional Chinese medicine reproduction. It has the highest outpatient volume in Shanghai, with over 400,000 patients each year. Nearly 10,000 IVF cycles are performed each year, accounting for one-fifth of the total cycles among the 18 reproductive centers in the city. The scale of Assisted Reproductive Technology (ART) at Renji stands at the top in Shanghai, and the ART treatment success rate is internationally leading. According to the quality control data from the Shanghai Municipal Health Commission, Renji Reproductive Center has ranked first in terms of live birth rates and live birth numbers for the past five years. It is also the sole reproductive medicine facility in Shanghai that ranks among the top ten experts in the Fudan edition of China Hospital Specialty Rankings. In 2019, it became China’s first center to acquire the DNV & RTAC Health System Certification for Assisted Reproductive Technology. In 2021, MyBaby project, the result of the innovative combination of assisted reproductive technologies and blockchain technology, was launched. It is currently the first application in the industry that combines international third-party DNV data certification with blockchain technology to meet patients' expectations for higher-quality clinical diagnosis and treatment technologies. The innovation was granted international patents.

Based on a solid clinical foundation, the Renji Reproductive Team conducts clinical translational research on major diseases that affect reproductive health relying on the municipal key laboratory. Over the past five years, more than 70 major national, provincial and ministerial level projects have been granted, including the key R&D programs of the Ministry of Science and Technology (Chief Scientist), key projects of the National Natural Science Foundation of China, and key international cooperative projects of the National Natural Science Foundation. Furthermore, 10 high-quality clinical trials have been led by the center. The multi-center clinical study with the largest sample size of patients with recurrent implantation failure, led by Renji Reproductive Team, defined the clinical empiric treatment of prednisone and was ranked among the top ten clinical medical advances in "China's Important Medical Advances in 2023". Based on these findings, over 300 papers have been published, 8 invention patents have been granted, and 16 patents have been filed. The remarkable research finding were published in the top journals including the New England Journal of Medicine (NEJM), the Journal of the American Medical Association (JAMA), the Lancet, and Proceedings of the National Academy of Sciences of the United States of America (PNAS). Furthermore, the team has received numerous awards including the National Innovation and Strive Award, He Liang & He Li Foundation Science and Technology Progress Award, the First Prize of China Medical Science and Technology Award, the First Prize of Shanghai Medical Science and Technology Award, and Wuzhou Women’s Science and Technology Award for Clinical Medical Research Innovation.

Renji Reproductive Medicine Center has now established a relatively comprehensive disciplinary platform. In 2009, it led the establishment of the Infertility Diagnosis and Treatment Center of Shanghai Jiao Tong University. In 2010, the Assisted Reproduction and Eugenics Technology Center in Shanghai was founded. In 2012, with the approval of the Municipal Science Committee, the Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics was established. By 2013, it had expanded to include the National Research Center for Assisted Reproductive Technology and Reproductive Genetics Shanghai Branch as well as the Collaborative Innovation Center for Assisted Reproductive Technology and Reproductive Genetics of Shanghai Municipal Education Commission. In 2014, it set up the Training Base for Shanghai Assisted Reproductive Technology to train new recruits. In 2018, the Shanghai Quality Control Center for Assisted Reproductive Technology was established and affiliated to the center. In 2021, the Shanghai Fertility Protection and Reconstruction Center was included. In 2023, it was designated as a top priority clinical center and a key public health discipline in Shanghai.

Renji Reproductive Medicine Team will always uphold the concept of "benevolent heart, benevolent skills, revitalizing the world", and will continue to promote the standardization and advancement of clinical diagnosis, treatment, and scientific research levels of reproductive diseases in Shanghai and throughout the country. The team will also make active and unremitting efforts to promote Shanghai’s reproductive medicine to the whole country, as well as China’s reproductive medicine around the world.